{'fraction_non_alphanumeric': 0.04353562005277045, 'fraction_numerical': 0.0316622691292876, 'mean_word_length': 4.622222222222222, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
An overview of six clinical trials of aspirin in coronary heart disease.

Data from six randomized, placebo-controlled clinical trials of aspirin, involving a total of 10,703 post-myocardial infarction patients, have been compared and combined. An apparent heterogeneity of findings among the six trials with respect to all-cause mortality is noted (P = 0.08). The reasons for this heterogeneity are explored. Two common methods of combining the results of several trials--the logrank and the log odds ratio methods--yield two-sided P-values of 0.112 and 0.110, respectively, for the aspirin-placebo effect on all-cause mortality. Alternative statistical methods of combining the results of the six trials give two-sided P-values ranging from 0.017 to 0.487.